Typically, CCL25 is involved in T-cell recruitment to inflammation sites, but its cancer-related role varies with the tumor microenvironment [44].The CCR9/CCL25 signaling has also been suggested to positively influence the aggressiveness of HCC cells by affecting epithelial-mesenchymal transition markers, pointing to a potential therapeutic target to mitigate HCC metastasis [45]. The gene discussed is CCR9; the disease is cancer.